Over-regulation of miR-133b inhibits cell proliferation of cisplatin-induced NSCLC by PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.